Non-Hodgkin Lymphoma | Specialty

Braunschweig Makes the Case for Earlier Use of CAR T-Cell Therapy in DLBCL

February 16th 2021

CAR T-cell therapy has shown robust responses and curative potential in patients with diffuse large B-cell lymphoma, regardless of cytogenetics or age.

Epperla Elucidates on Excitement With Tafasitamab and Selinexor in DLBCL

February 15th 2021

Narendranath Epperla, MD, MS, expands on findings from the L-MIND trial in DLBCL, as well as the significance of selinexor and other options in the pipeline.

R/R DLBCL: Treating With Tafasitamab-Lenalidomide

February 12th 2021

Tafasitamab Combined With Lenalidomide in R/R DLBCL

February 12th 2021

Role of Venetoclax in Chronic Lymphocytic Leukemia

February 10th 2021

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

A Look at the ECOG 1912 and iLLUMINATE Trials

February 10th 2021

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

Dr. Ahmed on Axi-Cel Benefit in Patients With Primary Refractory LBCL

February 9th 2021

Sairah Ahmed, MD, discusses the efficacy of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with refractory large B-cell lymphoma (LBCL) who achieved complete remission (CR) to any prior treatment versus those who were primary refractory.

Response to Prior Therapy Predicts Outcomes With Axi-Cel in Refractory Large B-Cell Lymphoma

February 9th 2021

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

Liso-Cel Responses Not Impacted By Prior Anti-CD19 Therapy in Relapsed/Refractory Large B-Cell Lymphoma

February 8th 2021

February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Relapsed/Refractory CLL Treatment: Addressing Unmet Needs

February 8th 2021

FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma

February 5th 2021

February 5, 2021 - The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.

FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma

February 5th 2021

February 5, 2021 - The FDA has approved lisocabtagene maraleucel for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.

R/R DLBCL: Second-Line Treatment Options

February 5th 2021

DLBCL: Treating Patients Following Relapse on Frontline Therapy

February 5th 2021

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Surge of New Drugs Fuels Optimism in Pediatric Oncology

February 4th 2021

The landscape for pediatric oncology drugs expanded dramatically last year, with 8 new drugs or indications specifically approved for children compared with just 47 for treatment and supportive care products from the early 1950s through 2019.

DPX-Survivac/Cyclophosphamide Plus Pembrolizumab Shows Early Promise in Relapsed/Refractory DLBCL

February 3rd 2021

Neil Berinstein, MD, discussed the early promise with this T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

A Look at the ELEVATE-TN and ASCEND Trials

February 3rd 2021

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia

February 3rd 2021

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.